comparemela.com

Latest Breaking News On - Pedro ferreira - Page 8 : comparemela.com

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

In HFpEF, Do MRA Users Get as Much Benefit From an SGLT2 Inhibitor?

Mineralocorticoid receptor antagonist use does not affect empagliflozin benefit in HFpEF

The benefit of the SGLT2 inhibitor empagliflozin in patients with HF with preserved ejection fraction did not differ between those who did or did not receive mineralocorticoid receptor antagonists, researchers reported.In a prespecified secondary analysis of the EMPEROR-Preserved trial of patients with HFpEF, researchers found that while the effect of empagliflozin (Jardiance, Boehringer

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.